Fortilink-TS Ti cage in back fusion for lumbar disc disease with mild spondylolisthesis
Official title: Post-market Clinical Study of the Fortilink-TS Ti
Run by BAAT Medical Products B.V. · NCT07834736 · Data updated 2026-11-12
This observational study tests the safety and performance of the Fortilink-TS Ti cage in adults undergoing posterior lumbar interbody fusion for degenerative disc disease with up to grade I spondylolisthesis, followed for one year.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | BAAT Medical Products B.V. Industry-sponsored |
| Locations | 2 sites (Madrid, Madrid and 1 other locations) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | September 22, 2026 |
| Trial ID | NCT07834736 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with degenerative lumbar disc disease at one or two contiguous levels between L2 and S1 and up to grade I spondylolisthesis, who have completed at least six months of non-operative treatment and can provide informed consent.
✕Probably not a fit
Patients with active infections, severe osteoporosis, spine tumors, or conditions that excessively stress the bones or implants may have a lower likelihood of benefiting.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This PMCF (post-market clinical follow-up) study collects data during routine care to monitor the Fortilink-TS Ti cage used in intervertebral fusion. About 50 participants are enrolled at two hospitals to document safety, surgical outcomes, and implant performance up to 12 months after surgery. Data come from medical history, intraoperative details, and standard follow-up assessments. The study uses no changes to standard treatment or follow-up beyond what patients would normally receive. The device has been on the market since 2020, and this study aims to actively gather real-world experience in the intended patient group.
Why it matters
Potential benefit: If successful, the study may provide real-world evidence that supports continued safe use and performance of the Fortilink-TS Ti cage in this patient population.
How similar studies have gone: Prior real-world data exist for Fortilink-TS Ti since 2020, but this PMCF study adds prospective, device-specific patient data in routine care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Willing and able to give voluntary informed consent 2. Skeletally mature patients 3. At least 6 months of non-operative treatment 4. Degenerative disc disease (DDD) of the lumbar spine at one or two contiguous levels between L2 and S1, with DDD being defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies, and/or up to grade 1 spondylolisthesis of the lumbar spine at one or two contiguous levels between L2 and S1 Exclusion Criteria: 1. Active systematic infection or an active infection at the operative site 2. A demonstrated allergy or sensitivity to any of the implanted materials 3. Severe osteoporosis (confirmed by imaging in the patient's medical history or during screening) 4. Primary or metastatic tumours affecting the spine (confirmed by imaging in the patient's medical history or during screening) 5. Conditions that may place excessive stresses on the bones and the implants, including but not limited to morbid obesity or other degenerative diseases, at the discretion of the investigator 6. Patients whose ability to follow postoperative restrictions, precautions and rehabilitation programs is limited 7. Fractures, severe deformities or a severe instability in the area of surgery (confirmed by imaging in the patient's medical history or during screening) 8. A medical or surgical situation that would preclude the benefit of surgery 9. Pregnancy 10. Patient's denial for operative treatment, post-operative rehabilitation program, follow up appointments and/or participation in the trial 11. Protocol specified surgical technique cannot be followed for the subject 12. Any other reason (in the judgment of the investigator).
Where it's running
-
Clinica Santa Elena
Madrid, Madrid, Spain Recruiting -
Centro Médico Asturias
Oviedo, Principality of Asturias, Spain Recruiting
Study contacts
- Study coordinator: Tess Jimenez - van Dam, MSc
- Email: tess@baatmedical.com
- Phone: +31 - (0)6 - 267 18 663
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fortilink-TC Ti cage use in lumbar fusion for back pain
This study tests how safe and effective the Fortilink-TC Ti interbody cage works in adults undergoing lumbar spine fusion for degenerative disc disease with mild spondylolisthesis.
-
Bone marrow concentrate injection added to lumbar microdiscectomy
This trial tests whether adding a bone marrow aspirate concentrate injection during lumbar microdiscectomy helps adults recover better than surgery alone.
-
LDGraft in one-level lumbar fusion for degenerative disc disease
This study tests LDGraft in adults with one-level lumbar degenerative disc disease to see if it can help with surgery outcomes.
-
Comparing fusion surgery and non-surgical treatment for low back pain
This study tests whether fusion surgery or a structured non-surgical treatment works better for people with chronic low back pain from degenerative disc disease.
-
Adding CORUS-LX to two-level (L4–S1) lumbar fusion
This trial will test whether adding the CORUS-LX device to standard surgery helps adults having two-level (L4–S1) lumbar fusion for degenerative disc disease and radiculopathy.
-
IDCT (Intradiscal Cell Therapy) for single-level mild-to-moderate lumbar degenerative disc disease
This will test whether injecting IDCT (rebonuputemcel) into one degenerating lower-back disc can reduce chronic low back pain in adults with mild-to-moderate lumbar degenerative disc disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.